# Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

> **NCT03608033** · PHASE3 · TERMINATED · sponsor: **Omeros Corporation** · enrollment: 360 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **BIOLOGICAL:** OMS721
- **OTHER:** Vehicle (D5W or saline)

## Key facts

- **NCT ID:** NCT03608033
- **Lead sponsor:** Omeros Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-05
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-01-12
- **Target enrollment:** 360 (ACTUAL)
- **Why stopped:** IA did not meet the prespecified primary endpoint.
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608033, "Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT03608033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*